A recent subanalysis of data from the PEGASUS-TIMI 54 trial indicates a favourable balance between the efficacy and safety of ticagrelor in patients with prior myocardial infarction (MI), irrespective of their renal function. These results support the long-term use of ticagrelor in patients with chronic kidney disease and prior MI.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sarnak, M. J. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108, 2154–2169 (2003).
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C.-Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296–1305 (2004).
Fox, C. S. et al. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction in patients with chronic kidney disease: a report from the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network Registry. Circulation 121, 357–365 (2010).
Dumaine, R. L. et al. Renal function, atherothrombosis extent, and outcomes in high-risk patients. Am. Heart J. 158, 141–148.e1 (2009).
Magnani, G. et al. Efficacy and safety of ticagrelor for long-term secondary prevention of atherothrombotic events in relation to renal function: insights from the PEGASUS-TIMI 54 trial. Eur. Heart J. http://dx.doi.org/10.1093/eurheartj/ehv482 (2015).
Bonaca, M. P. et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N. Engl. J. Med. 372, 1791–1800 (2015).
James, S. et al. Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation 122, 1056–1067 (2010).
Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001–2015 (2007).
Mega, J. L. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366, 9–19 (2012).
Acknowledgements
We thank John. W. Eikelboom (Population Health Research Institute, Canada) for his critical review of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
N.C.C. has received a travel grant from Sanofi and honorarium from Bayer. J.B. declares no competing interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Chan, N., Bosch, J. Net benefit of ticagrelor in patients with chronic kidney disease. Nat Rev Nephrol 12, 10–11 (2016). https://doi.org/10.1038/nrneph.2015.196
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2015.196
